Merck enlists 4D Pharma's microbiome platform in a bid to build a new class of vaccines
Merck has signed a research deal with 4D Pharma to use its MicroRX platform to turn living bacteria into vaccines.
The collaboration comes in the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
